Form 4: Aclaris Therapeutics Director Andrew Schiff Reports Significant Equity Grants and RSU Conversion

Aclaris Therapeutics, Inc. Director Andrew N. Schiff reported the acquisition of new stock options and restricted stock units, alongside the conversion of previously vested restricted stock units into common stock.

Summary

• Andrew N. Schiff, a Director of Aclaris Therapeutics, Inc. (ACRS), reported several equity transactions in a recent SEC Form 4 filing.
• On June 5, 2025, Mr. Schiff was granted 42,350 stock options with an exercise price of $1.56 per share. These options are set to vest in twelve equal monthly installments commencing on July 5, 2025, subject to his continuous service.
• Also on June 5, 2025, he received a grant of 11,580 Restricted Stock Units (RSUs), which will vest in a single installment on June 5, 2026, contingent on his continuous service.
• On June 6, 2025, 4,793 Restricted Stock Units vested and were subsequently converted into 4,793 shares of Aclaris Therapeutics common stock.
• Following these transactions, Mr. Schiff directly beneficially owns 13,960 shares of common stock.
• He also indirectly holds 434,455 shares of common stock through Aisling Capital IV LP, though he disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
• His derivative holdings now include 42,350 stock options and 11,580 Restricted Stock Units.
• All reported grants were made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.

Sentiment

Score: 7

Explanation: The sentiment is positive as the director received new equity grants and converted vested units, aligning their interests with the company's performance. There are no reported sales or negative transactions.

Positives

• Grant of 42,350 stock options, providing future potential upside tied to the company's stock performance.
• Grant of 11,580 Restricted Stock Units, further aligning the director's interests with shareholder value.
• Conversion of 4,793 Restricted Stock Units into common stock, increasing direct share ownership.
• The grants are part of a standard non-employee director compensation policy, indicating routine and structured compensation.

Negatives

• No explicit negative transactions, such as large sales or dispositions without corresponding acquisitions, are reported in this Form 4.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 434,455 common shares by Aisling Capital IV, LP, where Dr. Andrew Schiff is a managing member of the general partner. Dr. Schiff disclaims beneficial ownership except for his pecuniary interest therein.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholder value, as the value of the options and RSUs is tied to the company's stock performance.

Next Steps

• Continued vesting of 42,350 stock options in twelve equal monthly installments commencing July 5, 2025.
• Vesting of 11,580 Restricted Stock Units on June 5, 2026.

Key Dates

Keywords

Aclaris Therapeutics, ACRS, Andrew N. Schiff, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership, Aisling Capital